The research panel
Once a month, we send one short check-in. Three questions. Two minutes. Your anonymized answers, in aggregate, shape our reporting on what GLP-1 outcomes actually look like in the real world, not just in pharma-funded trials.
Why this matters
Every published GLP-1 trial is paid for by the company that makes the drug. STEP trials are funded by Novo Nordisk. SURMOUNT trials are funded by Eli Lilly. Trial protocols select for the kind of patient most likely to succeed on the drug and tolerate the side effects. Real-world outcomes look different, and almost nobody is measuring them at scale outside of insurance claims data, which has its own gaps.
We are building a real-world outcome data set that includes the things claims data does not measure: how patients actually feel, when they want to quit, what works to manage nausea, what happens after they stop. This data will inform editorial reporting on GLP Chart, and over time may inform academic research and post-market safety studies.
What we collect
When you join, we capture your answers to four optional questions: drug, dose, primary indication, and insurance plan. After that, the monthly check-in is three questions:
- Weight change. Up, down, or held steady over the past month, and roughly how much.
- Side effect intensity. A 0-to-3 scale across nausea, GI, energy, and quality of life.
- Still on the drug? Yes, no (and a one-tap reason), or switching.
That is it. No long surveys, no tracking pixels in the email, no recurring requests to refer a friend. One email a month, three questions, opt out any time.
What we never do
- We never share your name, email, or any identifying information with any third party.
- We never share individual records with anyone, ever. Only aggregate numbers.
- We never share your data with any program in the GLP Chart comparison.
- We never sell your email address. We never use it for advertising outside our own newsletter.
- We never share your data with your insurance plan or your employer.
- We never claim the data is FDA-supervised or HIPAA-regulated. It is not. This is voluntary.
The consent (plain English version)
By joining the research panel, you agree:
- We can send you a monthly check-in email asking three short questions about your GLP-1 use and outcomes.
- Your answers are stored in our newsletter system (Beehiiv) and are linked to your email address on our side. You can ask us to delete your data any time by emailing hello@glpchart.com.
- We may publish aggregate findings (for example, "of 1,200 panel members on compounded semaglutide, X% reported nausea at week 4") in our newsletter, on glpchart.com, and in press interviews. Aggregate findings never identify any individual.
- We may make de-identified aggregate findings available to academic researchers or pharma post-market safety teams under data-use agreements that prohibit re-identification. Individual records will never be shared.
- You can leave the panel by replying STOP to any check-in email or by emailing hello@glpchart.com. Leaving the panel means we stop sending check-ins. You stay subscribed to the regular Monday digest unless you also unsubscribe from that.
- This is voluntary research participation, not a clinical trial. GLP Chart is not a medical provider. The check-ins are not medical care. Talk to a licensed clinician about your actual treatment.
Consent version: v1 (2026-05-28). If we update the consent terms, we will email you the new version and ask you to re-confirm. You can refuse the new version and leave the panel without losing your regular newsletter subscription.
Join the panel
Fill in the four questions below and check the consent box. If you are not already subscribed to the Monday digest, this will subscribe you. If you are already subscribed, this adds you to the panel segment.
